<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01869361</url>
  </required_header>
  <id_info>
    <org_study_id>IRB13-00533</org_study_id>
    <nct_id>NCT01869361</nct_id>
  </id_info>
  <brief_title>Indomethacin for Tocolysis</brief_title>
  <official_title>Randomized, Placebo Controlled Trial of Indomethacin for Tocolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetroHealth Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MetroHealth Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Indomethacin is frequently used as a tocolytic, however there is currently only
      scant evidence to support its efficacy.

      Goals: To delay preterm delivery by 48 hours and to examine longer latency periods and
      maternal and neonatal outcomes Methods: Randomized placebo-controlled trial of indomethacin
      for tocolysis. Women with a singleton pregnancy between 23w0d and 31w6d in preterm labor
      randomly assigned to 50mg indomethacin by mouth followed by 25mg by mouth every 6hour for 48
      hours or placebo. Patients receive betamethasone for fetal lung maturity, if not previously
      administered, and magnesium sulfate for neuroprotection. Ultrasound performed before
      initiation of study drug and after completion of study medication for amniotic fluid index
      and fetal cardiac assessment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>delivery within 48 hours</measure>
    <time_frame>48 hours after enrollment</time_frame>
    <description>The percentage of patients remaining undelivered after 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>delivery within 7 days</measure>
    <time_frame>7 days after enrollment</time_frame>
    <description>The percentage of patients remaining undelivered after 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delivery before 37 weeks</measure>
    <time_frame>participants will be followed for the duration of pregnancy through their postpartum period, an expected time of up to 20 weeks</time_frame>
    <description>The percentage of patients remaining undelivered until 37 weeks gestational age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal and Fetal Complications</measure>
    <time_frame>participants will be followed for the duration of pregnancy through their postpartum period and neonatal hospital stay, an expected time of up to 24 weeks</time_frame>
    <description>composite of maternal intolerance of the drug, birth weight, gestational age, neonatal morbidities, changes in amniotic fluid volume, fetal cardiac assessment, or premature constriction of the ductus arteriosus.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Preterm Labor</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patient will be given a loading dose of 50mg placebo by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indomethacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patient will be given a loading dose of 50mg indomethacin by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>Study drug</description>
    <arm_group_label>Indomethacin</arm_group_label>
    <other_name>Indocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm labor as defined by regular uterine contractions (at least 6/hour) with
             cervical change of at least 1 cm or cervical shortening on transvaginal ultrasound
             less than 25mm of functional length

          -  Gestational age 23w0d to 31w6d weeks

          -  Singleton

          -  ≥ 18 years old

          -  Able to consent in English

        Exclusion Criteria:

          -  Major congenital anomalies associated with an increased risk of newborn death

          -  Multiple fetal gestation (2+)

          -  Known intrauterine fetal demise

          -  Non-reassuring fetal status requiring delivery

          -  Preterm premature rupture of membranes (PPROM)

          -  Suspected or known intrauterine infection

          -  Placenta previa

          -  Maternal allergy or contraindication to indomethacin (peptic ulcer disease,
             thrombocytopenia, coagulopathy, renal or hepatic dysfunction)

          -  Inevitable delivery (cervix ≥6cm dilated)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly S Gibson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MetroHealth Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Mercer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MetroHealth Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly S Gibson, MD</last_name>
    <phone>2167787076</phone>
    <email>kgibson@metrohealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kelly S Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>American College of Obstetricians and Gynecologists; Committee on Practice Bulletins—Obstetrics. ACOG practice bulletin no. 127: Management of preterm labor. Obstet Gynecol. 2012 Jun;119(6):1308-17. doi: 10.1097/AOG.0b013e31825af2f0.</citation>
    <PMID>22617615</PMID>
  </reference>
  <reference>
    <citation>Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ. 2012 Oct 9;345:e6226. doi: 10.1136/bmj.e6226. Review.</citation>
    <PMID>23048010</PMID>
  </reference>
  <reference>
    <citation>Hayes E, Moroz L, Pizzi L, Baxter J. A cost decision analysis of 4 tocolytic drugs. Am J Obstet Gynecol. 2007 Oct;197(4):383.e1-6.</citation>
    <PMID>17904969</PMID>
  </reference>
  <reference>
    <citation>Abramovici A, Cantu J, Jenkins SM. Tocolytic therapy for acute preterm labor. Obstet Gynecol Clin North Am. 2012 Mar;39(1):77-87. doi: 10.1016/j.ogc.2011.12.003. Epub 2012 Jan 4. Review.</citation>
    <PMID>22370109</PMID>
  </reference>
  <reference>
    <citation>Zuckerman H, Shalev E, Gilad G, Katzuni E. Further study of the inhibition of premature labor by indomethacin. Part II double-blind study. J Perinat Med. 1984;12(1):25-9.</citation>
    <PMID>6374098</PMID>
  </reference>
  <reference>
    <citation>Niebyl JR, Blake DA, White RD, Kumor KM, Dubin NH, Robinson JC, Egner PG. The inhibition of premature labor with indomethacin. Am J Obstet Gynecol. 1980 Apr 15;136(8):1014-9.</citation>
    <PMID>7369252</PMID>
  </reference>
  <reference>
    <citation>Panter KR, Hannah ME, Amankwah KS, Ohlsson A, Jefferies AL, Farine D. The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo-controlled trial. Br J Obstet Gynaecol. 1999 May;106(5):467-73.</citation>
    <PMID>10430197</PMID>
  </reference>
  <reference>
    <citation>Amin SB, Sinkin RA, Glantz JC. Metaanalysis of the effect of antenatal indomethacin on neonatal outcomes. Am J Obstet Gynecol. 2007 Nov;197(5):486.e1-10.</citation>
    <PMID>17980183</PMID>
  </reference>
  <reference>
    <citation>Sood BG, Lulic-Botica M, Holzhausen KA, Pruder S, Kellogg H, Salari V, Thomas R. The risk of necrotizing enterocolitis after indomethacin tocolysis. Pediatrics. 2011 Jul;128(1):e54-62. doi: 10.1542/peds.2011-0265. Epub 2011 Jun 20.</citation>
    <PMID>21690109</PMID>
  </reference>
  <reference>
    <citation>Loe SM, Sanchez-Ramos L, Kaunitz AM. Assessing the neonatal safety of indomethacin tocolysis: a systematic review with meta-analysis. Obstet Gynecol. 2005 Jul;106(1):173-9. Review.</citation>
    <PMID>15994634</PMID>
  </reference>
  <reference>
    <citation>Cordero L, Nankervis CA, Gardner D, Giannone PJ. The effects of indomethacin tocolysis on the postnatal response of the ductus arteriosus to indomethacin in extremely low birth weight infants. J Perinatol. 2007 Jan;27(1):22-7. Epub 2006 Oct 19.</citation>
    <PMID>17053778</PMID>
  </reference>
  <reference>
    <citation>Eronen M, Pesonen E, Kurki T, Ylikorkala O, Hallman M. The effects of indomethacin and a beta-sympathomimetic agent on the fetal ductus arteriosus during treatment of premature labor: a randomized double-blind study. Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):141-6.</citation>
    <PMID>1986601</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>May 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MetroHealth Medical Center</investigator_affiliation>
    <investigator_full_name>Kelly S Gibson</investigator_full_name>
    <investigator_title>Maternal Fetal Medicine</investigator_title>
  </responsible_party>
  <keyword>preterm labor</keyword>
  <keyword>tocolysis</keyword>
  <keyword>indomethacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

